VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
28.04.2024 10:00
Small- & MicroCap Investment
28.04.2024 09:30
Small- & MicroCap Investment
28.04.2024 09:00
Small- & MicroCap Investment
EUROPA NACHRICHTEN
ADHOC
Do, 25.03.2021 07:45
pta20210325011
Business news for the stock market
Marinomed Biotech AG: Marinomed Biotech AG enrolls first patient in clinical study of inhaled Carragelose to treat COVID-19 infectionsKorneuburg (pta011/25.03.2021/07:45) - 25 March 2021
* Clinical study of inhaled Carragelose (Inhaleen) in hospitalized patients suffering from COVID-19
Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that the first patient has been treated in a clinical trial evaluating Inhaleen, a Carragelose-based inhalation solution, in hospitalized patients with COVID-19. The study will evaluate safety and efficacy of inhaled Carragelose for the treatment of moderate COVID-19, i. e. patients with respiratory COVID-19 symptoms who require hospitalization but not intensive care. The randomized, double-blind, placebo-controlled trial will recruit 204 recently hospitalized patients with confirmed COVID-19 who will be randomized less than 48 hours after admission to the hospital. Patients will inhale 3 times a day for 7 minutes with either Inhaleen (1.2 mg/ml Carragelose; total dose iota-carrageenan per day: 5.05 mg) or a placebo control for 5 days. As primary endpoint, the trial aims to demonstrate that Inhaleen inhalation improves the clinical status of hospitalized patients on day 8 compared to placebo. The clinical status will be documented according to the WHO-8-Category scale, which ranges from 1 (not hospitalized, no limitation of activities) to 8 (death). Secondary endpoints include the number of patients requiring critical care support, supplemental oxygen requirement, and PCR diagnosis of SARS-CoV-2 or other respiratory viruses. The latter is designed to evaluate efficacy of Inhaleen against viral pneumonias caused by viruses other than SARS-CoV-2. The trial will be conducted at three hospitals based in Vienna, Austria. Dr. Arschang Valipour, Head of Internal Medicine and Pneumology at the Vienna-based hospital Klinik Floridsdorf, will lead the clinical trial program. If Inhaleen is proven safe and effective for the treatment of COVID-19 in hospitalized patients, Marinomed plans to use the clinical trial results to seek certification for the inhaled Carragelose formulation from the relevant authorities. "We still see a very high medical need for effective therapies against COVID-19. Currently, doctors have only limited treatment options beyond supportive care and cannot help much while a patient's condition is deteriorating," said Dr. Eva Prieschl-Grassauer, Chief Scientific Officer at Marinomed. "With this trial of inhaled Carragelose, we hope to show that Inhaleen can be an effective treatment for recently hospitalized patients with COVID-19. Additionally, we intend to show that Inhaleen can aid faster recovery and prevent the disease from further damaging a patients' lungs or progressing to more severe stages," Dr. Prieschl-Grassauer, added. "We have done comprehensive preclinical work showing the efficacy of Carragelose against SARS-CoV-2. Together with the recent clinical results, which showed that iota-carrageenan can be effectively used for COVID-19 prophylaxis, we are very confident that Inhaleen will be an effective treatment for COVID-19 patients." A clinical trial of Carragelose-based nasal spray recently showed high efficacy in the prevention of COVID-19 in hospital workers with an 80 % reduction in cases. The independent investigator-initiated study was conducted in Argentina with an iota-carrageenan nasal spray identical to Marinomed's Carragelose nasal spray, which is marketed as an antiviral OTC product in many countries and already approved for the treatment and prevention of several other viral respiratory diseases, including endemic Coronaviruses.
About Carragelose®:
About Marinomed Biotech AG
For further inquiries contact:
International Media Contact
Media Contact Austria
Disclaimer
(Ende)
PRESSETEXT.TV
Walter Oblin sieht Post auf Wachstumskurs 18.04.2023 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|